What You Should Know: - Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology. - Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. -
Read More
Tempus
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know: - Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone. - This multi-omics approach is being used by Actuate Therapeutics in support
Read More
Tempus Launches Real-World Data-Driven Program to Accelerate Precision Oncology Research
What You Should Know: - Precision Medicine company Tempus announced the launch of Tempus+, a program connecting medical centers across the U.S. like Stanford Cancer Center, Baylor College of Medicine, Rush University Medical Center, and UCLA Jonsson Comprehensive Cancer Center, to advance cancer research and provide access to Tempus’ library of more than five million de-identified research records. - Tempus’ data library and data analytics platform, Lens, can now be used by researchers to
Read More
Children’s Oncology Group Taps Tempus to Provide Genomic Sequencing for Pediatric Cancer Patients
What You Should Know: -Tempus, an $8B precision medicine company, is providing genomic sequencing for 300 eligible pediatric cancer patients annually through their new collaboration with the Children’s Oncology Group (COG). Tempus’ support for COG – a leader in pediatric oncology research – will assist with matching patients to clinical trials like the Pediatric MATCH Screening Trial APEC1621SC (NCT03155620), which is studying the effectiveness of genetic testing-directed treatment in
Read More
Geisinger & Tempus Create AI Model to Identify Structural Heart Disease
What You Should Know: - Tempus, an $8B precision medicine company, announced a collaborative study with Geisinger focusing on artificial intelligence (AI) model that can accurately identify patients at increased risk of undiagnosed structural heart disease (SHD). The study addresses a critical diagnostic gap – SHD is a progressive disease that affects the valves, walls, chambers, and muscles of the heart, and causes debilitating symptoms or death, yet many patients with the disease go
Read More
Tempus Launches Psychiatric Real-World Data Collaboration
What You Should Know: - Tempus, an $8B precision medicine company, announced the launch of a new psychiatric real-world data program to leverage real-world data to inform mental health treatment. - Tempus N+ is a collaboration between provider institutions across the country and Tempus to build an infrastructure for data-driven research – providers can seamlessly and securely contribute molecular and clinical data, and in turn, their clinicians and researchers can access a
Read More
Tempus Launches Pathology-Driven AI Platform
What You Should Know: - Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide. - With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would
Read More
GSK Launches Accelerated Clinical Trial with Tempus
What You Should Know: - Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022. - This trial’s data-driven design and site selection
Read More
Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment
What You Should Know: - Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease. - By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More
CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform
What You Should Know: - CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer. - CancerIQ’s technology enables hospitals to use genomics
to personalize the prevention and early detection of cancer. - Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading
Read More
